Filing Signals

Source: SEC EDGAR Compiled 2026-09-14 08:28 UTC All 21 checks passing

← All events

Galera Therapeutics, Inc.

CIK 1563577 GRTX·Pharmaceutical Preparations · All EDGAR filings ↗

Going concern Filing comparison

Galera Therapeutics, Inc.'s going-concern disclosure changed

Substantial doubt about ability to continue as a going concern Risk-factor language only

The principal risks and uncertainties affecting our business include the following: • We are a biopharmaceutical company with a limited operating history and have not generated any revenue from product sales. We have incurred significant operating losses since our inception and anticipate that we will incur continued losses for the foreseeable future. • Our ability to continue as a going concern is dependent on obtaining additional funding, and failure to secure such funding could significantly impair our operations. • We previously halted clinical development of all but one of our product…
Evidence
Blank check
No
Comparable
Yes
Current state
risk_factor_only
Current state label
Risk-factor language only
Direction
eased
Located in
risk factors / forward-looking statements only
Prior filed
2025-03-31
Prior form
10-K
Prior state
substantial_doubt
Prior state label
Substantial doubt about ability to continue as a going concern
Source
ASC 205-40 going-concern note comparison
Why
Disclosure about the company's ability to continue as a going concern changed compared with its previous report.